Central Nervous System Therapeutic Market by Disease (Neurovascular Diseases, CNS Trauma, Mental Health [Anxiety Disorders, Epilepsy, Mood Disorders, Psychotic Disorders, and Others], Neurodegenerative Diseases [Alzheimer's Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington's Disease, Amyotrophic Lateral Sclerosis, and Others], Infectious Diseases, CNS Cancer, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global central nervous system therapeutic market size was valued at USD 116.2 billion in 2020 and is projected to expand at a CAGR of 7.7 % during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of central nervous system disorders and the rising need for efficient therapeutics treatments.

Central Nervous System (CNS) is a critical part of nervous system, it is a complex system of nerves and cells which sends and receives signals from brain and spinal cord other areas of the body, such as the sensory organs, arms, hands, legs, and feet. A neurosurgeon is a clinician who specializes in the diagnosis and surgical treatment of diseases of the central and peripheral nervous systems, such as congenital anomalies, trauma, tumours, vascular disorders, brain or spine infections, stroke, or degenerative spine diseases. The spinal cord's functioning is affected by diseases such as autoimmune and inflammatory disorders, genetic disorders, cancers, and neurodegenerative diseases. CNS therapeutic drugs are utilized to address these conditions. In the treatment of neurological disorders, getting medications to the central nervous system (CNS) is difficult. Drugs can be injected directly into the CNS or given in a systematic manner (e.g., by intravenous injection) to have a specific effect in the CNS. The blood-brain barrier (BBB), which limits medications from reaching the brain tissue, is a critical barrier for CNS drug delivery.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing prevalence of neurological disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s and growing geriatric population around the world are projected to boost the market growth during the forecast period.
• Increasing awareness regarding the neurological disorders is expected to propel the market growth in the coming years.
• Advancements in diagnostics, therapeutics and drug development techniques is anticipated to drive the market growth in the forecasted period.
• Upcoming therapeutics for CNS disorders are expected to boost the market growth in coming years.
• Stringent drug approval framework is anticipated to impede the market growth during the forecast period.
• Higher price for advanced treatments is expected to hamper the market growth during the coming years.
• Increased R&D investments by government and private organisations is expected to create lucrative opportunities for the market players.

Scope of the Report

The report on the global central nervous system therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Neurodegenerative disease segment is expected to account for a key share of the market
Based on disease, the central nervous system therapeutic market is segmented into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, CNS cancer, others. The mental health segment is further sub segmented into anxiety disorders, epilepsy, mood disorders, psychotic disorders, others. The neurodegenerative diseases segment is further sub segmented into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, amyotrophic lateral sclerosis, and others. The neurodegenerative disease segment is expected to account for a key share of the market during the forecast period owing to increasing prevalence of neurodegenerative diseases such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. Furthermore, the category is projected to be driven by strong pipeline candidates for the treatment of neurological disease.

On the other hand, the mental health segment is anticipated to expand at a rapid pace during the forecast period owing to larger number of patients with anxiety disorder and epilepsy. Further, upcoming new drug development for the treatment of psychotic disorders is attributed to offer lucrative growth opportunities for the market.

CNS cancer segment is also anticipated to expand at a rapid pace during the forecast period owing to increasing prevalence and demand for cancer treatment. glioblastoma multiforme is the most common brain cancer in the world among all the brain cancer. In addition, increased R&D efforts by pharmaceutical firms, as well as increased government and private institution funding, are projected to boost the use of CNS drugs in cancer therapy. The segment of neurodegenerative diseases and mental health together accounted for more than 75.0 %. The growth of these segment can be attributable to high prevalence and technological partnerships, which will continue to exhibit their dominance throughout the forecast period.

North America is anticipated to dominate the market
On the basis of regions, the central nervous system therapeutic market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to presence of key players in the market and their initiatives to develop novel therapies for CNS disorders. Furthermore, the increasing prevalence of incidence of mental health and neurodegenerative disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s disease, and epilepsy is also driving the market growth. Pharmaceutical companies' awareness campaigns about CNS disease diagnosis and treatment, as well as better reimbursement policies for CNS disease treatment, have increased the region's treatment rate.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to healthcare infrastructural development in developing economies such as China and India and need for better treatment facilities. Furthermore, increasing public awareness of mental health issues, as well as government and non-profit organizations efforts, are boosting market development. Many non-profit organizations in countries like China and India provide treatment for individuals with central nervous system disorders.